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The host microbiota has emerged
a third player in interactions
between hosts and viral patho-
gens. This opens new possibilities
to use different tools to modulate
the intestinal microbial composi-
tion, aimed at reducing the risk of
or treating viral enteric infections.Gut Microbiota Shape Enteric
Virus Infection
Classically, virologists have considered
viral infection a bidirectional (virus–host
cell) process with no participation of
external factors other than the immune
system. However, this classical picture
is changing in view of how some viruses
exploit specific and direct interactions
with the commensal microbiota from
the mucosal niches they infect.
Accumulating evidence has demon-
strated a key interaction between gut
microbiota and intestinal viruses that
leads to infection in mouse models. For
example, the infection of mice by intesti-
nal-replicating poliovirus [1] depended on
the presence of intestinal bacteria. A sim-
ilar situation has been recently described
for the two viral groups responsible for the
major percentage of acute gastroenteritis
(AGE) worldwide: rotavirus (RV) and nor-
ovirus (NoV). RV infections are the leading
cause of deaths due to AGE in children
under the age of 5, while NoVs are
associated with approximately 20%
AGE episodes globally. Experiments ingnotobiotic models or animals with
depleted intestinal microbiota have dem-
onstrated the role of enteric bacteria in the
infections of both viruses. Mice treated
with antibiotics showed a decreased
infectivity of murine RV [2], and this treat-
ment also caused a similar effect in the
murine NoV (MNoV) model [3]. Reinforc-
ing this concept, it has been recently
shown that the gut microbiota prompt
MNoV replication through an antagonistic
mechanism to interferon-lambda (IFN-l)
[4]. These facts conflict with the generally
accepted role of the microbiota as a
shield against pathogen infection, owing
to their immunoregulatory functions and
colonization-resistance effect (Box 1).
Recent results with human NoV (hNoV)
also argue in favor of the microbiota’s role
in infectivity, although the existence of
contradictory results indicates that more
research is needed to have a clear picture
of the mechanisms. While several cellular
lines are available for infection by human
RVs, it was not until recently that hNoVs
were successfully replicated in vitro in B
cells with the participation of the micro-
biota. The presence of gut commensal
bacteria allowed hNoV infection in human
lymphocytes, with the purified human
blood group antigen (HBGA) substance
H having the same effect: enhancement
of hNoV attachment and replication [3].
HBGA-like substances expressed on the
surface of certain enteric bacteria may be
targets for viral attachment, and this has
been demonstrated in some strains [5].
Many studies have correlated hNoV sus-
ceptibility with the secretor status (syn-
thesis of H-antigen at mucosal sites
dictated by a functional FUT2 gene),
and it has been recently demonstrated
that secretor status also influences RV
vaccine (RVV) immunogenicity [6]. The
secretor phenotype has also been shown
to impact intestinal microbial composition
[7]. However, the hNoV tropism is still
under discussion, and a recent in vitrohNoV replicating system has been set
up that uses organoids derived from
intestinal epithelial stem cells without a
microbiota presence [8]. This has pro-
moted a profound debate that has been
further fueled by other conflicting results;
although enteric bacteria such as Enter-
obacter cloacae, which expresses H-like
antigens on its surface, enhanced in vitro
hNoV B cells infectivity [3], the adminis-
tration of E. cloacae in a gnotobiotic pig
model antagonized NoV infection [9].
How Can the Gut Microbiota Be
Manipulated to Fight against
Enteric Viruses?
Currently, the role of microbiota in AGE
remains elusive, but new applications
beyond the state of the art are foreseen.
Oral administration of classic members of
the gut microbiota (e.g., Lactobacillus
and Bifidobacterium) has proven benefi-
cial in mitigating the severity of viral AGE.
While this protective effect is mainly attrib-
uted to immunoregulation (e.g., enhance-
ment of specific anti-RV IgA production)
or to a simple competition for attachment
to host cells (Box 1), the microbiota now
appear as a ‘double-edged sword’ that
can also promote infectivity of AGE-caus-
ing viruses. If the intestinal microbiota
restrict infectivity but, in parallel, promote
viral stability, attachment/entry, or act as a
‘Trojan horse’ that helps viruses reach
their infection sites, then differences in
the microbial composition could explain
differences in viral susceptibility. Such dif-
ferences were suggested to be responsi-
ble for the lack of RVV (an attenuated
virus) efficacy in specific population
groups. In a study conducted during a
children RV vaccination program in
Ghana, it was concluded that the intesti-
nal microbiota of the population that pos-
itively responded to RVV were similar to
those of age-matched European popula-
tions that have a high RVV response,
whereas those of nonresponders differed
substantially [10]. Furthermore, anti-hNoVTrends in Biotechnology, Month Year, Vol. xx, No. yy 1
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Box 1. Mechanisms of Intestinal Virus–Microbiota–Host interactions
Several mechanisms have been established or hypothesized on how intestinal viruses interact with the microbiota, influencing viral infectivity. Both promoting and
antagonistic effects on infection are found (Figure I). The promoting mechanisms include:
 Virus binding to bacterial products (e.g., lipopolysaccharide or HBGA-like substances [15]) increases virion stability and protects it from physical stresses.
 hNoV-loaded bacteria could be transcytosed by intestinal epithelial cells (e.g., M cells from Peyer’s patches), allowing the pass through the intestinal barrier and
subsequent infection of immune cells (macrophages, dendritic cells, and B cells).
The antagonistic mechanisms include:
 Members of the microbiota specifically bind viruses, washing them out and impairing their binding to the intestinal epithelium [9].
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Figure I. Promoting and Antagonistic Effects of Microbiota in Acute Gastroenteritis. HBGA, human blood group antigen; IFN, interferon; Ig,
immunoglobulin.and anti-RV IgA levels in adults explained
the differences in the intestinal microbial
composition linked to the secretor (FUT2)
status [7]. Currently, there is no commer-
cially available vaccine for hNoV, and
microbiota studies would be necessary
to examine if the efficacy of a putative2 Trends in Biotechnology, Month Year, Vol. xx, No. yyhNoV oral vaccine would also depend
on the microbiota composition.
Remarkable gut microbiome and viral
infectivity associations have been
described in independent studies with
European adults [7] and in the AfricanRVV trial [10]. Thus, increased numbers
of Bacteroidetes have been linked to the
nonsecretor status (FUT2–/–) in adults [7],
while members of this phylum were also
increased in children with low RVV
response [10]. Furthermore, the higher
presence of specific microbial taxa, such
TIBTEC 1597 No. of Pages 4as Ruminococcaceae, was linked to
lower IgA titers to RV and hNoV in healthy
adults. In parallel, higher proportions of
Ruminococcus were detected in Ghana-
ian RVV nonresponders [10]. A negative
correlation was also found for some spe-
cific anti-inflammatory bacterial species,
such as Faecalibacterium prausnitzii, and
hNoV susceptibility. Contrarily, others,
such as Akkermansia muciniphila, were
related to increased RV susceptibility
[7], and Streptococcus boviswas present
in higher numbers in RVV responders
[10].
While these associations do not neces-
sarily imply causality, host glycobiology,
microbiota, and viral infectivity seem inter-
connected, and more research is needed
to prove this theory and to discard the
occurrence of confounders (e.g., age,
diet, geographical location). Thus, studies
in adults should be complemented with
























Figure 1. Possible Microbiota-Based Strategies
strategies to manipulate the intestinal microbiota and m
the promotion or direct use of particular bacteria for redu
infection for the development of more effective oral vaof 5, particularly for RV, andwith follow-up
studies where the AGE incidence must be
monitored. However, the finding of gut
microbiota members as potential bio-
markers of viral infectivity and/or risk of
viral infection leads to a series of interest-
ing questions that will probably lay the
foundation for the development of new
alternative therapies (Figure 1).
Would it be possible to increase the effi-
cacy of oral vaccination by novel combi-
nations of specific viral strains and
bacteria? Positive correlations between
microbiota/viral infectivity can be
exploited. Specifically, microbiota analy-
ses linked to the efficacy of vaccines (e.g.,
RVV) in different population settings [10]
must be performed to identify candidate
bacteria. Can antibiotics that target spe-
cific microbial groups be used to reduce
the risk of RV and hNoV infection? Sur-
prisingly, antibiotherapy appears as an
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Oral vaccines
for Antiviral Therapies. The different proposed
odulate viral infectivity are depicted. Strategies include
ction of infectivity or the enhancement of the efficacy of
ccines.the risk–benefits of this approach must
be considered. Could some of the identi-
fied biomarkers be used to counteract
viral infection? These are anaerobic and
fastidious bacteria; however, they are
being proposed as new emerging probi-
otics. Dietary intervention strategies can
also be envisaged. An intimate interrela-
tionship between diet, immune system,
and microbiota has been recognized
when explaining risk and susceptibility
to disease [11]. Diet has been described
as the most powerful tool to modulate
and shape gut microbiota, and diet inter-
vention, including probiotics, prebiotics,
and symbiotics, has been proposed for
the treatment/prevention of microbiota-
related diseases such as colorectal can-
cer, cardiovascular disease, obesity, and
inflammatory bowel syndrome. While this
still represents an unexplored field in virol-
ogy, the recent anti-NoV effect of vitamin
A supplementation has been explained
through an increase in the Lactobacillus
levels to modulate the microbiota, which
results in IFN-b-mediated immunomodu-
lation [12]. Fecal transplantation has been
proven as another tool for modifying the
gut microbiome, and it is useful for treat-
ing recalcitrant intestinal infections [13].
Although RV and hNoV cause self-limited
AGE, the use of microbial cocktails or
consortia for treating viral AGE through
fecal transplantation can be anticipated.
Finally, the influence of the secretor phe-
notype on viral AGE inspires the idea of
host mucosal glycosylation as a likely tar-
get for modulating RV/hNoV replication.
The microbiota impact the mucosal gly-
cosylation status by modulating the
expression of host glycosyltransferases
[14] and by providing a source of multiple
glycosidases that act on the mucosa. If
the microbiota’s modification of the host
glycans contributes to the infection pro-
cess, either by promoting or limiting infec-
tion, this would provide a new repertory of
therapeutic tools, including the use of
specific glycosidases (purified enzymesTrends in Biotechnology, Month Year, Vol. xx, No. yy 3
TIBTEC 1597 No. of Pages 4or glycosidase-expressing bacteria) to
shape mucosal glycosylation and inter-
fere with virus replication.
The virus–bacteria coevolution that has
taken place over millions of years has
established networks in the virus–host–
microbiota triangle, where viruses exploit
the microbiota and their related products
to modulate some aspects of the infection
process. Science remains far from estab-
lishing causal effects, and both direct and
indirect effects may be present. As new
mechanistic data on this triangular inter-
play are obtained, new opportunities will
appear for therapeutic interventions and
for viral preventive strategies.
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